HRAS and head and neck squamous cell carcinoma: Tipifarnib is currently under clinical development for treatment of HRAS-mutant thyroid cancer, head and neck squamous cell carcinoma (HNSCC), and non-small-cell lung carcinoma (NSCLC) [31].